ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients

Efficacy and Safety of an ER-formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients Under Consideration of Quality of Life Parameters

The aim of the observational study is to investigate the safety of oxcarbazepine extended release (ER) during long-term therapy in epileptic patients. In addition, quality of life parameters should be documented if assessed.

Inclusion Criteria:

• patients with focal epileptic seizures with or without secondary generalised tonic-clonic seizures
• mono- or combination therapy
• male and female from the age of 6

Exclusion Criteria:

• hypersensitivity to oxcarbazepine MR or one of its excipients